REFRACTORY AML
Clinical trials for REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY AML trials appear
Sign up with your email to follow new studies for REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CLL-1 CAR-NK cells) designed to find and attack leukemia cells. The main goals …
Matched conditions: REFRACTORY AML
Phase: PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 17, 2026 05:29 UTC
-
New drug combo shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests whether adding the experimental drug ziftomenib to standard AML treatments is safe and effective. About 420 adults with specific genetic mutations (NPM1 or KMT2A) will receive one of three drug combinations. The goal is to find the best dose and see i…
Matched conditions: REFRACTORY AML
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC